Riskpilot← Back to searchSign inGet full accessVLVbio AB
ABActiveOrg 5569396533Hästholmsvägen 32Manufacture of pharmaceutical preparations · NACE 2120Est. 20137 employees
Revenue 2024
SEK 12,1M
-11% vs 2023
EBITDA margin
-12.6%
-54% vs 2023
Equity ratio
0.3%
Financial strength
Net profit 2024
SEK -1,6M
-24% vs 2023
| Revenue | SEK 12,1M | -11% |
| EBITDA | SEK -1,5M | -54% |
| Net profit | SEK -1,6M | -24% |
| Total assets | SEK 14,8M | +12% |
| Equity | SEK 50K | +0% |
| Employees | 7 | — |
Legal name
VLVbio AB
Org number
5569396533
Legal form
Aktiebolag
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
20 augusti 2013
Share capital
SEK 50 000
Employees
7 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Firman tecknas ensam av Burmester, Madeleine Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall bedriva forskning och utveckling, produktion och distribution av läkemedel och diagnostiska produkter och konsultativ verksamhet inom dessa områden samt därmed förenlig verksamhet.
Address
Hästholmsvägen 32
Phone
+46706421685
Email
vd@vlvbio.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 10 414 | 13 932 | 9 861 | 10 912 | 11 175 | 13 311 | 13 528 | 12 089 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | 993 | 441 | −362 | 455 | −4 203 | −3 440 | −4 009 | −422 | −995 | −1 528 |
| Depreciation & amort. | −189 | −171 | −143 | −255 | −153 | −153 | −157 | −177 | −187 | −0 |
| EBIT | 804 | 270 | −505 | 200 | −4 356 | −3 593 | −4 166 | −599 | −1 182 | −1 528 |
| Net financials | — | — | −3 | −1 | −11 | −50 | −66 | −83 | −97 | −60 |
| Profit before tax | 720 | 177 | −508 | 199 | 0 | −3 643 | −4 232 | −682 | −1 279 | −1 589 |
| Tax | −56 | −61 | −0 | 59 | −0 | −0 | −55 | −0 | −0 | −0 |
| Net profit | 664 | 116 | −508 | 258 | −4 367 | −3 643 | −4 287 | −682 | −1 279 | −1 589 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 5 573 | 5 343 | 4 395 | 5 952 | 1 748 | 6 180 | 10 531 | 12 202 | 13 196 | 14 752 |
| Equity | 3 139 | 3 255 | 2 747 | 3 005 | 50 | 50 | 50 | 50 | 50 | 50 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 2 350 | 1 912 | 1 472 | 2 771 | 1 698 | 6 130 | 10 481 | 12 152 | 13 146 | 14 702 |
| Total debt | 2 350 | 1 912 | 1 472 | 2 771 | 1 698 | 6 130 | 10 481 | 12 152 | 13 146 | 14 702 |
EBITDA margin
-12.6%
This company
15.8%
Market median
-180% vs market
20152024
Equity ratio
0.3%
This company
38.2%
Market median
-99% vs market
20152024
Return on equity
-3178.0%
This company
18.4%
Market median
-17372% vs market
20152024
Net profit margin
-13.1%
This company
8.1%
Market median
-262% vs market
20152024
Asset turnover
0.82×
This company
1.12×
Market median
+27% vs market
20152024
Debt / equity
294.04×
This company
0.62×
Market median
-47326% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
SB Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
TN Audit | Audit | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Chairman | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
DIAPHARAM GROUP INC | Company | 100.0% | 100.0% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
DIAPHARAM GROUP INC
VLVbio AB (this company)Board members of VLVbio AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Slavica Brnjic | Chief Executive Officer | 0 companies |
| Tomas Nöjd | Audit | 0 companies |
| Sven Odd Swarting | Board of Directors | 0 companies |
| Madeleine Burmester | Chairman | 0 companies |
| Stig Tryggve Linder | Board of Directors | 0 companies |
| Michael Allen Hambleton | Board of Directors | 0 companies |